Diagnosis and treatment of hemangiopericytoma in the central nervous system

J Cancer Res Ther. 2018;14(7):1578-1582. doi: 10.4103/jcrt.JCRT_210_18.

Abstract

Objective: This study aimed to explore the clinical characteristics and treatment of the hemangiopericytoma (HPC) in the central nervous system.

Materials and methods: Clinical data from 14 patients with HPC in the central nervous system who were followed up for 12-107 months were retrospectively analyzed, and relevant literature was reviewed.

Results: All 14 patients underwent surgery and postoperative pathologic diagnosis, including 8 cases of total excision, 3 cases of subtotal excision, and 3 cases of partial excision. There were 7 recurrent cases (50%, 4 cases of total excision, 1 case of subtotal excision, and 2 cases of partial excision, none of them received postoperative radiotherapy) with a median relapse time of 39 months, where the median relapse time after total excision was 41.5 months, and after nontotal excision was 17 months. In addition, patients could survive for a long time after reoperation following relapse and after receiving postoperative radiotherapy.

Conclusion: The diagnosis of HPC depends on the pathology. Currently, the surgery and postoperative radiotherapy provide a good treatment results, while the wholeness of surgical resection is of particular importance.

Keywords: Central nervous system; clinical features; hemangiopericytoma; radiotherapy.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Central Nervous System Neoplasms / diagnosis*
  • Central Nervous System Neoplasms / therapy*
  • Child
  • Combined Modality Therapy
  • Disease Management
  • Female
  • Follow-Up Studies
  • Hemangiopericytoma / diagnosis*
  • Hemangiopericytoma / therapy*
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Multimodal Imaging
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Young Adult